Table 1.
Univariate survival analysis of baseline metastatic sites
| Outcome | Liver | Lung | Bone | Lymph | ||||
|---|---|---|---|---|---|---|---|---|
| Yes(n = 71) | No(n = 82) | Yes(n = 107) | No(n = 46) | Yes(n = 90) | No(n = 63) | Yes(n = 87) | No(n = 66) | |
| Median PFS(Q1,Q3), day | 43(40–162) | 127(46–305) | 85(42–236) | 45(41–243) | 49(41–208) | 128(43–271) | 85(42–249) | 82(41–210) |
| HR(95%CI) | 1.97(1.40–2.76) | 0.90(0.63–1.30) | 1.47(1.04- 2.08) | 0.90(0.65 −1.26) | ||||
| P-value | < 0.001 | 0.585 | 0.030 | 0.549 | ||||
| Median OS(Q1,Q3), day | 246(127–499) | 592(317–816) | 434(218–786) | 373(169–616) | ||||
| HR (95%CI) | 2.57 (1.73 – 3.81) | 0.67 (0.45 – 1.01) | 1.32 (0.88 – 1.97) | 1.36 (0.91 – 2.04) | ||||
| P-value | < 0.001 | 0.056 | 0.175 | 0.131 | ||||
Q1—First quartile Q3—Third quartile